In addition, glutamine antagonism inhibits both glucose and glutamine metabolism in cancers, along with increasing the nutrient contents of TME, whereas CD8+T cells synchronously increase acetate metabolism to fuel TCA-coupled OXPHOS and achieve more prolonged survival upon glutamine inhibition (Leone et al., 2019). Here, CD8A is linked to cancer.